Press Release
Press Release
Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer
Data Presented at the 2009 Joint Meeting of the
The data from study XL184-201 were presented today during a poster
session at the 2009 Joint Meeting of the
The study evaluates the safety, tolerability, and clinical activity of
XL184 at continuous daily doses of 175 mg or 125 mg in patients with
previously treated GBM, including some patients who had received prior
antiangiogenic therapy. A total of 46 patients in first or second
relapse were enrolled and dosed with 175 mg of XL184 administered daily,
and enrollment at this dose level is complete. Due to frequent dose
interruptions and reductions, the study was amended earlier this year to
initiate a new cohort of patients receiving 125mg. As of
Tumor response was determined by an independent and blinded radiology
facility (IRF) per modified MacDonald criteria. As of
Follow up for the patients receiving 125 mg is relatively short, with
the first patient enrolled in late
The safety experience, to date, is primarily derived from the 175 mg dose level. The most frequently occurring Grade 3 and Grade 4 adverse events (>5%) regardless of relationship to drug were: fatigue, headache, palmar-plantar erythrodysesthesia, confusional state, alanine aminotransferase increase, convulsion, lymphopenia, hypophosphatemia, lipase increase, diarrhea, aspartate aminotransferase increase, and gait disturbance. Incidence of Grade 3 or 4 adverse events often associated with antiangiogenic therapy were: hypertension (2%), bleeding events (9%), thromboembolic event (4%), pulmonary embolism (7%), craniotomy wound dehiscence (4%), and perirectal abscess (2%). Of the 46 patients treated at the 175 mg dose level, 13 have had at least one serious adverse event (SAE) related to XL184. In addition, 89% of patients at this dose level had a dose interruption of XL184. Dose interruptions (14/18) and reductions (6/18) were observed in patients at the 125 mg dose level. The most frequent investigator reported non-serious adverse events resulting in dose reduction or interruption included: fatigue, palmar-plantar erythrodysesthesia, transaminase elevation, lipase and amylase elevation, and mucositis.
“The updated data from patients treated with the 175 mg dose of XL184 is
consistent with what we have reported previously and continue to
demonstrate that the compound is clinically active,” said Michael M.
Morrissey, Ph.D. president of research and development at
About XL184
XL184 (BMS-907351) is an investigational oral inhibitor of MET, VEGFR2,
and RET that produces antiangiogenic, antiproliferative, and
antiinvasive effects in preclinical tumor models. MET is mutationally
activated in some tumor types, such as hereditary and sporadic papillary
renal cell carcinoma and some head and neck cancers. More frequently,
MET is either over-expressed or activated in the absence of mutation in
glioblastomas, breast carcinomas, some gastric cancers, and other solid
tumors. MET amplification has been demonstrated in some NSCLCs.
Expression of VEGF has been observed in a variety of cancers and has
been associated with prognostic significance. Targeting the VEGF
receptor has been recognized as a potential anti-cancer strategy in
multiple tumors. Dual targeting of MET and VEGFR2 blocks two of the
major mechanisms tumors use to overcome hypoxia. Activated RET is
involved in cell signaling cascades that regulate cell proliferation,
migration, differentiation, and survival. RET is mutationally activated
in papillary thyroid cancer (PTC) and in both familial and sporadic
forms of medullary thyroid cancer (MTC).
About
About
Exelixis Forward-Looking Statements
This press release contains forward-looking statements by
Bristol-Myers Squibb Forward-Looking Statement
This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995 relating
to the development and commercialization of certain compounds. Such
forward-looking statements are based on current expectations and involve
inherent risks and uncertainties, including factors that could delay,
divert or change any of them, and could cause actual outcomes and
results to differ materially from current expectations. No
forward-looking statement can be guaranteed. Among other risks, there
can be no guarantee that the clinical trial mentioned in this release
will support a regulatory filing or that the compound will receive
regulatory approval or become a commercially successful product.
Forward-looking statements in the press release should be evaluated
together with the many uncertainties that affect
Source:
Bristol-Myers Squibb Company
Brian Henry, 609-252-3337
Director,
Business Communications
brian.henry@bms.com
or
Exelixis,
Inc.
Charles Butler, 650-837-7277
Vice President, Corporate
Communications & Investor Relations
cbutler@exelixis.com